Select your Market
Overview Q2 2026
|
Q2 2026 |
Organic change |
Change |
|---|---|---|---|
Group net sales | 5.4 | 4.1 | 3.4 |
EBITDA pre | 1.6 | 9.3 | 9.4 |
Life Science sales | 2.4 | 8.0 | 6.4 |
Healthcare sales | 2.2 | –3.4 | 2.4 |
Electronics sales | 0.9 | 11.7 | –1.7 |
Our second-quarter performance confirms continued momentum from important growth drivers across all the industries we serve. Going forward, we remain focused on increasing speed, flexibility and scalability across the company while delivering profitable growth and sustainable value creation.
Detailed information about the development of our business in the first half of 2026.
Downloads for the Media
Press Releases
Performance driven by continued demand in Process Solutions, Rare Diseases and Semiconductor Solutions.
2026/08/06
Our Q3 2026 results will be published on November 12, 2026, at 7 a.m. (CEST). Our conference call for the media will take place at 09:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST)
Our Q4 2026 results will be published on March 4, 2027, at 7 a.m. (CET). Our conference call for the media will take place at 09:30 a.m. (CET), and the conference call for analysts at 2 p.m. (CET)
